5 results
To determine the safety and efficacy of Dimebon in patients with mild-to-moderate Huntington Disease
Time to recurrence of sustained VT and/or appropriate ICD therapy; ATP or shock
To determine the safety and efficacy of Dimebon in patients with mild to moderate Huntington Disease
The main objective of this study is to compare the occurrence of next ICD shock therapy for VT or VF in patients with hospital presentation for an ICD shock therapy for VT or VF, with a history of a myocardial infarction, between patients randomized…
To evaluate the long-term safety and tolerability of Dimebon in AD patients who have successfully completed 26 weeks of blinded treatment in the CONNECTION Study (DIM14) (hereafter referred to as *CONNECTION*).